Barclays’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-40,600
| Closed | -$3.45M | – | 5290 |
|
|
2020
Q3 | $3.45M | Sell |
40,600
-21,800
| -35% | -$1.1M | ﹤0.01% | 1658 |
|
|
2020
Q2 | $2.21M | Sell |
62,400
-62,400
| -50% | -$1.82M | ﹤0.01% | 2029 |
|
|
2020
Q1 | $1.68M | Sell |
124,800
-100,300
| -45% | -$1.69M | ﹤0.01% | 2440 |
|
|
2019
Q4 | $4.76M | Buy |
225,100
+219,100
| +3,652% | +$3.87M | ﹤0.01% | 2056 |
|
|
2019
Q3 | $80K | Sell |
6,000
-9,600
| -62% | -$141K | ﹤0.01% | 5643 |
|
|
2019
Q2 | $216K | Sell |
15,600
-3,800
| -20% | -$57.2K | ﹤0.01% | 5039 |
|
|
2019
Q1 | $373K | Sell |
19,400
-141,900
| -88% | -$2.29M | ﹤0.01% | 4346 |
|
|
2018
Q4 | $2.3M | Buy |
161,300
+107,200
| +198% | +$2.13M | ﹤0.01% | 2268 |
|
|
2018
Q3 | $1.13M | Sell |
54,100
-9,300
| -15% | -$220K | ﹤0.01% | 3511 |
|
|
2018
Q2 | $1.5M | Sell |
63,400
-56,600
| -47% | -$1.14M | ﹤0.01% | 2843 |
|
|
2018
Q1 | $1.75M | Buy |
120,000
+62,700
| +109% | +$1.02M | ﹤0.01% | 2605 |
|
|
2017
Q4 | $926K | Buy |
57,300
+26,400
| +85% | +$312K | ﹤0.01% | 3195 |
|
|
2017
Q3 | $432K | Buy |
30,900
+12,100
| +64% | +$121K | ﹤0.01% | 3765 |
|
|
2017
Q2 | $166K | Sell |
18,800
-15,500
| -45% | -$109K | ﹤0.01% | 4524 |
|
|
2017
Q1 | $222K | Sell |
34,300
-3,600
| -9% | -$18.2K | ﹤0.01% | 4208 |
|
|
2016
Q4 | $139K | Buy |
37,900
+29,000
| +326% | +$85.8K | ﹤0.01% | 4515 |
|
|
2016
Q3 | $29K | Sell |
8,900
-2,000
| -18% | -$5.59K | ﹤0.01% | 5291 |
|
|
2016
Q2 | $25K | Buy |
10,900
+1,300
| +14% | +$4.34K | ﹤0.01% | 5190 |
|
|
2016
Q1 | $19K | Buy |
9,600
+6,600
| +220% | +$14.8K | ﹤0.01% | 5250 |
|
|
2015
Q4 | $9K | Sell |
3,000
-3,500
| -54% | -$9.77K | ﹤0.01% | 5441 |
|
|
2015
Q3 | $7K | Sell |
6,500
-212,600
| -97% | -$543K | ﹤0.01% | 5946 |
|
|
2015
Q2 | $876K | Buy |
219,100
+209,900
| +2,282% | +$858K | ﹤0.01% | 2986 |
|
|
2015
Q1 | $28K | Sell |
9,200
-65,100
| -88% | -$283K | ﹤0.01% | 5659 |
|
|
2014
Q4 | $297K | Buy |
74,300
+10,500
| +16% | +$41.5K | ﹤0.01% | 4322 |
|
|
2014
Q3 | $191K | Buy |
63,800
+10,500
| +20% | +$35.5K | ﹤0.01% | 4786 |
|
|
2014
Q2 | $160K | Sell |
53,300
-50,200
| -49% | -$184K | ﹤0.01% | 5028 |
|
|
2014
Q1 | $414K | Buy |
103,500
+20,800
| +25% | +$103K | ﹤0.01% | 4115 |
|
|
2013
Q4 | $331K | Buy |
82,700
+47,300
| +134% | +$211K | ﹤0.01% | 4499 |
|
|
2013
Q3 | $212K | Buy |
35,400
+9,700
| +38% | +$55.8K | ﹤0.01% | 4983 |
|
|
2013
Q2 | $140K | Buy |
+25,700
| New | +$84.4K | ﹤0.01% | 5517 |
|
Barclays's IMMU Position: Q4 2020 in Review
Barclays sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 535,506 shares — an estimated $45.5M sold.
Barclays first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $45.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Barclays reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Barclays sold 535,506 Immunomedics Inc shares in Q4 2020, an estimated $45.5M.
- Barclays first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
- Barclays's Immunomedics Inc position peaked at $45.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.